GOV Stock Chart & Stats
€122.35
€3.40(2.37%)
At close: 4:00 PM EDT
€122.35
€3.40(2.37%)
Day’s Range― - ―
52-Week Range€113.35 - €304.00
Previous CloseN/A
Volume0.00
Average Volume (3M)61.00
Market Cap
€8.05B
Enterprise Value€10.98K
Total Cash (Recent Filing)€534.90M
Total Debt (Recent Filing)€948.40M
Price to Earnings (P/E)24.5
Beta0.24
Next Earnings
Nov 04, 2026EPS Estimate
1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.36
Shares Outstanding69,354,200
10 Day Avg. Volume117
30 Day Avg. Volume61
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€145.06Price Target Upside18.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)5.74
Revenue Forecast (FY)€2.90B
Bulls Say, Bears Say
Bulls Say
Recurring Consumable Revenue ModelThe disposable Omnipod model creates recurring revenue as patients replace pods regularly, supporting visibility beyond one-time hardware sales. This repeat usage can strengthen customer retention, improve planning, and provide a durable foundation for continued growth as the installed base expands.
Strong Growth And Expanding MarginsInsulet is combining rapid revenue expansion with high and improving margins, indicating operating leverage from scale and manufacturing productivity. Sustaining this combination would support stronger earnings growth, provide resources for investment, and reinforce the economics of the Omnipod platform.
International Growth And Access ExpansionStrong international growth and broader payer access expand the addressable market for Omnipod beyond its established U.S. base. Rising coverage and overseas adoption can improve long-term customer acquisition, diversify growth sources, and support the company’s stated multi-year expansion opportunity.
Bears Say
Type 2 Retention Execution RiskWeak onboarding and first-90-day retention among type 2 customers could reduce the lifetime value of new users and make growth investments less efficient. Although management describes the issue as addressable, corrective actions must improve utilization before this customer segment becomes a durable growth contributor.
Uneven Free Cash Flow ConversionInsulet generates meaningful positive cash, but uneven conversion from earnings and a recent decline in free cash flow reduce the quality and flexibility of that growth. Lower cash generation could constrain investment capacity, particularly while the company funds manufacturing expansion and corrective initiatives.
Net Margin VolatilityThe movement in net margin shows that strong gross and operating performance has not translated into consistently stable bottom-line profitability. Continued volatility below the operating line could make earnings less predictable and limit confidence that revenue growth will compound proportionally into durable net income.
Insulet News
GOV FAQ
What was Insulet’s price range in the past 12 months?
Insulet lowest stock price was €113.35 and its highest was €304.00 in the past 12 months.
What is Insulet’s market cap?
Insulet’s market cap is €8.05B.
When is Insulet’s upcoming earnings report date?
Insulet’s upcoming earnings report date is Nov 04, 2026 which is in 33 days.
How were Insulet’s earnings last quarter?
Insulet released its earnings results on Aug 05, 2026. The company reported €1.477 earnings per share for the quarter, beating the consensus estimate of €1.306 by €0.171.
Is Insulet overvalued?
According to Wall Street analysts Insulet’s price is currently Undervalued.
Does Insulet pay dividends?
Insulet does not currently pay dividends.
What is Insulet’s EPS estimate?
Insulet’s EPS estimate is 1.41.
How many shares outstanding does Insulet have?
Insulet has 69,354,200 shares outstanding.
What happened to Insulet’s price movement after its last earnings report?
Insulet reported an EPS of €1.477 in its last earnings report, beating expectations of €1.306. Following the earnings report the stock price went down -20%.
Which hedge fund is a major shareholder of Insulet?
Currently, no hedge funds are holding shares in DE:GOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insulet Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€145.06 (18.56% Upside)
€145.06 (18.56% Upside)
Blogger Sentiment
Bullish
DE:GOV Sentiment 64%
Sector Average 65%
Sector Average 65%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.25%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.77%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insulet
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
GOV Company Deck
GOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and financial performance — strong revenue, significant margin expansion, robust EPS growth, international strength, product and clinical progress, and solid liquidity — while transparently acknowledging a meaningful, addressable execution issue in onboarding and retaining type 2 customers that led to a modest downward revision to U.S. revenue outlook and a reassessment of longer-term assumptions. Management presented concrete actions (expanded customer care, sales compensation changes, sampling refinements, Omnipod Discover and data platform investments) to remediate retention and utilization in the first 90 days and expressed confidence these will translate into improved outcomes over time.View all DE:GOV earnings summariesGOV Revenue Breakdown
70.89% U.S. Omnipod
27.85% International Omnipod
1.26% Drug Delivery
GOV Stock 12 Month Forecast
Average Price Target
€145.06
▲(18.56% Upside)
Technical Analysis
Abbott Laboratories
―
Dexcom
―
Medtronic
―
Tandem Diabetes Care
―
Beta Bionics, Inc.
―